6000 Shoreline Court
South San Francisco
329 articles with Veracyte, Inc.
New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer
Veracyte, Inc. today announced new data demonstrating the prognostic utility of the company’s Decipher® Prostate genomic classifier among men with non-metastatic castration-resistant prostate cancer (nmCRPC) have been published online in JAMA Oncology.
First Molecular Subtyping Test to Gain Medicare Coverage to Inform Treatment for Individuals With Bladder Cancer
Veracyte, Inc., a global genomic diagnostics company, announced that Marc Stapley, chief executive officer, and Bonnie Anderson, executive chairwoman, are scheduled to participate in two upcoming virtual investor conferences
Veracyte, Inc. announced it has reached the terms of an agreement to acquire HalioDx in a transaction to further accelerate growth and strengthen Veracyte’s global leadership in cancer diagnostics.
Veracyte Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA Samples
Veracyte, Inc ., (Nasdaq: VCYT) announced today new data that show the company’s Afirma Xpression Atlas (XA) can identify clinically relevant gene fusions in thyroid nodule samples collected via fine needle aspiration (FNA). The findings, which will be presented June 4 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Veracyte, Inc., a global genomic diagnostics company, announced that Bonnie H. Anderson, chairman, chief executive officer and incoming executive chairman, and Marc Stapley, incoming chief executive officer, are scheduled to participate in two upcoming virtual investor conferences
Veracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic Classifier
Veracyte, Inc . (Nasdaq: VCYT) today announced new data from two studies that further demonstrate the Decipher ® Prostate Genomic Classifier (GC) provides prognostic information that can help physicians tailor treatment decisions for men with prostate cancer.
Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection
Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection Company to hold webcast to discuss findings on Thursday, May 20, at 10:00 a.m. ET
Veracyte, Inc., a global genomic diagnostics company, announced that Bonnie H. Anderson, chairman, chief executive officer and incoming executive chairman, and Marc Stapley, incoming chief executive officer, are scheduled to participate in two upcoming virtual investor conferences:.
Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy
Veracyte, Inc. (Nasdaq: VCYT) announced today new data demonstrating the ability of the Percepta® Genomic Atlas to detect alterations that may inform lung cancer treatment decisions for patients from the same small biopsy that was used for diagnosis. Study findings presented today at the American Thoracic Society (ATS) 2021 International Conference show
5/14/2021Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers.
Bonnie Anderson, Cofounder and CEO, to Assume Active Role as Executive Chairman; Marc Stapley to Become Chief Executive Officer
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2021, which were in line with its previously announced, preliminary first-quarter results.
Veracyte Announces New Data Relating to Prosigna Breast Cancer Test to Be Presented at ESMO Breast Cancer Virtual Congress
Veracyte, Inc. (Nasdaq: VCYT) announced today that new data relating to the Prosigna® Breast Cancer Gene Signature Assay will be presented at the European Society of Medical Oncology (ESMO) Breast Cancer Virtual Congress 2021 taking place May 5-8.
Veracyte to Unveil Practice-Changing Genomic Diagnostics Data Across Multiple Oncology Indications at 2021 ASCO
- Pivotal clinical validation data for Percepta Nasal Swab test in early lung cancer detection - - New data demonstrating ability of Decipher Prostate test to identify high metastasis risk in African American men -
Veracyte Announces Publication of Study Showing Robust Performance of Percepta GSC in Improving Lung Cancer Diagnosis
Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of a new study that demonstrates the robust performance of the Percepta Genomic Sequencing Classifier (GSC), a novel genomic test, in helping to improve lung cancer diagnosis.
Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its full financial results for the first quarter of 2021 after the close of market on Monday, May 10. Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Veracyte Announces Data for Pulmonology Portfolio to be Presented at American Thoracic Society 2021 International Conference
- New data support role of Percepta Genomic Atlas in genomic profiling for lung cancer patients – - Study suggests Envisia classifier can be successfully enabled on nCounter Analysis System -
Veracyte, Inc . (Nasdaq: VCYT) announced that Keith Kennedy, chief financial officer and chief operating officer, will retire from the company, effective May 15, 2021, following the company’s release of its full quarterly financial results
Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test
Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test First Patient Enrolled and Randomized in Study Utilizing LymphMark to Identify Patients with Untreated DLBCL Who May Potentially Benefit from Calquence in Combination with R-CHOP Therapy